Skip to content

PHASE

Pulmonary Hypertension Analysis via ClearSight Evaluation - Pulmonary Hypertension Analysis via ClearSight Evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON58527
Enrollment
300
Registered
2026-04-08
Start date
2026-04-13
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension High blood pressure in the arteries of the lungs

Interventions

Non-invasive arterial pressure waveforms are measured in patients suspected of pulmonary hypertension undergoing RHC treatment in the cardiac catheterization lab. Because the study specifically focuse
The data collection consists of two phases.Phase 1 involves obtaining 10 minutes of good waveform data in supine position and 10 minutes of good waveform data in sitting position using the ClearSight/

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: = 18 years of ageInformed consentPlanned rightsided heart catherisation for suspected of diagnosed pulmonary hypertensionAwake and sponteneously breathing and in the absence of anaesthesia

Exclusion criteria

Exclusion criteria: Inability to measure non-invasive finger blood pressure according to the instructions of the CS/EV1000/HemoSphere system's manualPatients with tricuspid stenosis or that have undergone the placement of a tricuspid valve clip (TriClip)Female patients with known pregnancyPatients with dialysis shuntPatients with severe intracardiac shunt or a congenital heart defectPatients with history of heart transplant, cardiac valve repair or valve replacement

Design outcomes

Primary

MeasureTime frame
The primary endpoint of the study is to assess whether the non-invasive arterial pressure waveform, measured at finger level, shows distinctive morphological features that can be used in the early detection of PH. The performance of the model is evaluated based on predictive accuracy, using the following parameters: sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and the area under the receiver operating characteristic curve (AUC).

Secondary

MeasureTime frame
The influence of additional parameters on model performance will be assessed. In addition, model performance for different subgroups of the patient population will be determined (biological sex, severity of PH underlying cause, positioning, e.g. supine or upright).

Countries

Netherlands

Contacts

Public ContactY.K. Lam

Amsterdam UMC

y.lam@amsterdamumc.nl0628799332

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Apr 23, 2026